key: cord-0876523-su8gexiw
authors: Sharun, Khan; Dhama, Kuldeep
title: India’s role in COVID-19 vaccine diplomacy
date: 2021-04-16
journal: J Travel Med
DOI: 10.1093/jtm/taab064
sha: 8dc97660ac789925146494ce67dfaeb409efc1f0
doc_id: 876523
cord_uid: su8gexiw

Indian vaccine manufacturers such as Serum Institute of India, Bharat Biotech, Dr Reddy’s Laboratories, Biological E Limited, Aurobindo Pharma, and Indian Immunologicals have already secured the license to manufacture major vaccine candidates. The ability of the country to manufacture cost-effective COVID-19 vaccines will help to meet the global vaccine requirements.

Indian vaccine manufacturers such as Serum Institute of India, Bharat Biotech, Dr. Reddy's Laboratories, Biological E Limited, Aurobindo Pharma, and Indian Immunologicals have already secured the license to manufacture major vaccine candidates. The ability of the country to manufacture cost-effective COVID-19 vaccines will help to meet the global vaccine requirements.

Key words: COVID-19; SARS-CoV-2; Vaccine diplomacy; India; Vaccination coverage;

Vaccine India is regarded as the vaccine manufacturing hub of the world, contributing 60% to the global vaccine supply. 1 The country has the capacity to manufacture well over 3 billion coronavirus disease 2019 (COVID-19) vaccine doses annually. 2 The ability of the country to produce low-cost COVID-19 vaccines will benefit low-income countries that cannot afford expensive vaccines. 3 vaccines on a large scale will help to meet the global vaccine requirements without causing an additional economic burden.

The authors received no funding in relation to this article.

All authors declare that there exist no commercial or financial relationships that could, in any way, lead to a potential conflict of interest.

KS and KD conceptualized the manuscript; KS wrote the first draft with input from KD; all authors contributed to revisions and approved the final manuscript. 

India's vaccine diplomacy aids global access to COVID-19 jabs

Covid-19 vaccine update -The Covid-19 vaccination race has just begun

India's cost-effective COVID-19 vaccine development initiatives

Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B 1.1.7 variant of SARS-CoV-2

Manufacturing capacity of Covishield 70-100 MM doses per month, Covaxin 150MM doses per year: DBT

Explained: The Covid-19 vaccines India is making, testing and supplying

Ministry of Science & Technology. Government Launches Mission COVID Suraksha to accelerate Indian COVID-19 Vaccine Development

Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment

None to be stated

The company is in talks with other manufacturers for production and further trials in humans.